Developmental Research program (DRP)
The principal goal of the Developmental Research Program is to fund promising early stage projects that address important translational objectives in prevention, early detection, and therapy of pancreatic carcinoma. Our principal intent for the Developmental Research Program is to bring novel translational research projects to the SPORE program. Key elements that determine priority in this program are innovation, novelty, and potential for success in translational pancreatic cancer research. All Developmental Funds will be awarded by competition based on submission of a NIH-style pilot project application. There is a requirement for clear evidence that the proposed project shows potential of developing into a larger research project that will involve human intervention for pancreatic cancer (diagnostic or therapeutic).    

2018 DRP Projects

PI

Title

Jennifer Black, PhD
Donald Durden, MD, PhD

Development of dual PI3K/BRD4 and triple PI3K/BRD4/CDK4/6 inhibitors for the treatment of pancreatic ductal adenocarcinoma (PDAC)

Michael Hollingsworth, PhD
James Talmadge, PhD

Adoptive Cellular Immunotherapy for Pancreatic Cancer
Sarah Holstein, MD, PhD

Geranylgeranyl diphosphate synthase inhibitor therapy for pancreatic adenocarcinoma

Amar Natarajan, PhD

Targeting apoptotic protein network for pancreatic cancer therapy

Dandan Zheng, PhD

Radiomic characterization of individual tumors for personalized pancreatic cancer care

2017 DRP Projects

PI

Title

Sarah Holstein, MD, PhD

Investigation of novel RAB inhibitors for the treatment of pancreatic cancer

Amar Natarajan, PhD

Chemical genetic screens to identify novel therapeutic combinations for pancreatic cancer therapy

2016 DRP Projects

PI

Title

Jixin Dong, PhD

Role of YAP-LPAR3 Axis in Pancreatic Cancer

Aaron Mohs, PhD

Multimodal Contrast Agents for Integrated Preoperative and Intraoperative Imaging of Pancreatic Cancer

Amar Natarajan, PhD

Chemical genetic screens to identify novel therapeutic combinations for pancreatic cancer therapy

Angie Rizzino, PhD

SOX2 and Rational Design of PDAC Targeted Therapeutics

James Talmadge, PhD

Novel tumor specific T-cell expansion for the treatment of pancreatic ductal adenocarcinomas

Nicholas Woods, PhD

Analysis of CTDP1-mediated ICL response and regulation in PDAC

2015 DRP Projects

PI

Title

Jennifer Black, PhD

Targeting Inhibitor of DNA Binding (Id) Proteins in Pancreatic Cancer

Pankaj Singh, PhD

Targeting Glutamine Metabolism to Overcome Gemcitabine Resistance in Pancreatic Cancer

Joyce Solheim, PhD

Mouse Models for Investigation of APLP2 as a Pancreatic Cancer Therapy Target

Jenny Wang, PhD

Targeting PDK4 to Overcome Drug Resistance in Pancreatic Cancer

2013 DRP Projects

PI

Title

Michael Brattain, PhD and Quan Ly, MD

Novel strategies in pancreatic cancer treatment

Kaustubh Datta, PhD

Effects of Zoledronic Acid on Pancreatic Tumor Cells

Chittibabu (Babu) Guda, PhD

Identification and characterization of pancreatic cancer subtypes using exome-sequencing data

Michael Hollingsworth, PhD

Inhibition of CDK5 as a Treatment for Pancreatic Cancer (year three)

Ram Mahato, PhD

Polymeric Nanomedicines for Co-Delivery of Gemcitabine and miRNA

Angie Rizzino, PhD

Effects of Zoledronic Acid on Pancreatic Tumor Cells

Polina Shcherbakova, PhD

DNA Polymerase d and ε Mutations in Pancreatic Cancer

Joyce Solheim, PhD

Optimizing Production of the Therapeutic Chemokine CCL21

2011-2012 DRP Projects

Michael Brattain, PhD and Quan Ly, MD

Pre-clinical Development of Novel Therapies for Pancreatic Cancer (Year 2)

Michael A. Hollingsworth, PhD

Inhibition of CDK5 as a treatment for pancreatic cancer (Year 2)

Amar Natarajan, PhD

Define the disease state of IKKb and develop small molecular inhibitors against it for pancreatic cancer therapy

Angie Rizzino, PhD

The Roles of Deubiquitinating Enzyme USP9X in Pancreatic Cancer

Polina Shcherbakova, PhD

Prevalence of DNA Polymerase δ Mutations in Colorectal Cancer

Simon Sherman, PhD

Prognostic Tools for Pancreatic Cancer Survival

Pankaj Singh, PhD

A metabolic approach for targeting gemcitabine resistance in pancreatic cancer

Jenny Wang, PhD

Unique Role of HIF1α in Colon Cancer Metastasis

2010 DRP Projects

Michael Brattain, PhD

Pre-clinical Development of Novel Therapies for Pancreatic Cancer

David Berkowitz, PhD (UNL)

A Novel Podophyllum Lignan-based Approach to Therapeutics for Pancreatic Cancer

Michael A. Hollingsworth, PhD

Inhibition of CDK5 as a treatment for pancreatic cancer

Joyce Solheim, PhD

Strategies to Decrease Immune Evasion and Growth of Pancreatic Cancer Cells